[CAS NO. 170632-47-0]  Lificiguat (YC-1)

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [170632-47-0]

Catalog
SLK-S7958
Brand
Selleck
CAS
170632-47-0

DESCRIPTION [170632-47-0]

Overview

MDLMFCD06407798
Molecular Weight304.34
Molecular FormulaC19H16N2O2
SMILESC(N1N=C(C=2C1=CC=CC2)C=3OC(CO)=CC3)C4=CC=CC=C4

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

1 mg5 mg10 mg
1 mM3.2858 mL16.4290 mL32.8580 mL
5 mM0.6572 mL3.2858 mL6.5716 mL
10 mM0.3286 mL1.6429 mL3.2858 mL
50 mM0.0657 mL0.3286 mL0.6572 mL

Description

Lificiguat (YC-1) is an nitric oxide (NO)-independent activator of and an inhibitor of .

Targets

sGC [1]HIF-1α [2]

In vitro

YC-1 is an allosteric activator of soluble guanylyl cyclase (sGC). YC-1 increases the catalytic rate of the enzyme and sensitizes the enzyme toward its gaseous activators nitric oxide or carbon monoxide. YC-1 alone activates the enzyme only 10-fold, but it potentiates the CO- and NO-dependent activation of sGC, resulting in stimulation of the highly purified enzyme that may be several hundred- to several thousand-fold . It inhibits platelet aggregation and vascular contraction and also inhibits HIF-1 activity in vitro. YC-1 completely blocks HIF-1α expression at the post-transcriptional level and consequently inhibits the transcription factor activity of HIF-1 in hepatoma cells cultured under hypoxic conditions, suggesting that these effects of YC-1 are likely to be linked with the oxygen-sensing pathway and not with the activation of soluble guanylyl cyclase.

In vivo

The administration of YC-1 to experimental animals results in the inhibition of the platelet-rich thrombosis and a decrease of the mean arterial pressure, which correlates with increased cGMP levels . YC-1 effectively inhibits tumor growth in tumor-bearing mice. The inhibition of HIF-1 activity in tumors from YC-1-treated mice is associated with blocked angiogenesis and an inhibition of tumor growth, while the anti-platelet aggregation effect of YC-1 does not appear to affect tumor growt.


Synonyms

2-Furanmethanol, 5-[1-(phenylmethyl)-1H-indazol-3-yl]-
5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol
YC 1
YC 1 (pharmaceutical)
1-Benzyl-3-(5-hydroxymethylfur-2-yl)indazole
Lificiguat
1-Benzyl-3-(5-hydroxymethyl-furan-2-yl)indazole
[5-(1-Benzyl-1H-indazol-3-yl)-furan-2-yl]-methanol
[5-(1-Benzylindazol-3-yl)furan-2-yl]methanol